Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cullinan Therapeutics (CGEM) Gains from Investment Securities: 2020-2023

Historic Gains from Investment Securities for Cullinan Therapeutics (CGEM) over the last 3 years, with Dec 2023 value amounting to -$9.1 million.

  • Cullinan Therapeutics' Gains from Investment Securities fell 275.15% to -$9.1 million in Q4 2023 from the same period last year, while for Dec 2023 it was $786,000, marking a year-over-year decrease of 97.92%. This contributed to the annual value of $10.4 million for FY2024, which is 334.60% up from last year.
  • According to the latest figures from Q4 2023, Cullinan Therapeutics' Gains from Investment Securities is -$9.1 million, which was down 297.30% from $4.6 million recorded in Q2 2023.
  • Over the past 5 years, Cullinan Therapeutics' Gains from Investment Securities peaked at $32.7 million during Q3 2022, and registered a low of -$9.1 million during Q4 2023.
  • Moreover, its 3-year median value for Gains from Investment Securities was $4.6 million (2021), whereas its average is $5.3 million.
  • Within the past 5 years, the most significant YoY rise in Cullinan Therapeutics' Gains from Investment Securities was 3,636.64% (2023), while the steepest drop was 275.15% (2023).
  • Cullinan Therapeutics' Gains from Investment Securities (Quarterly) stood at $4.6 million in 2020, then surged by 131.79% to $10.7 million in 2021, then crashed by 51.22% to $5.2 million in 2022, then crashed by 275.15% to -$9.1 million in 2023.
  • Its Gains from Investment Securities was -$9.1 million in Q4 2023, compared to $4.6 million in Q2 2023 and $75,000 in Q1 2023.